Efficacy with SOC cilta-cel. (A) Best response in all patients who underwent apheresis, patients who received cilta-cel infusion, patients who received cilta-cel infusion with conforming product, and patients who received cilta-cel infusion with conforming product and Flu/Cy lymphodepletion. (B) MRD negativity rates among patients who received infusion and were in CR with MRD data available. (C) PFS in all patients who underwent apheresis (n = 255). (D) PFS in patients receiving cilta-cel infusion (n = 236).